4 results match your criteria: "Abbondanza Eye Centers[Affiliation]"
Five-year corneal cross-linking outcomes: A Save Sight Keratoconus Registry Study.
Clin Exp Ophthalmol
January 2023
Specialty of Clinical Ophthalmology and Eye Health, Sydney Medical School, Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to determine the long-term outcomes of epithelium-off cross-linking (CXL) in keratoconus patients.
Methods: An observational registry study from 41 centres across 5 countries was carried out. Primary outcomes included the mean change in visual acuity (VA), Kmax, K2, and thinnest corneal thickness (TCT) at 1-5 years.
Long-term Results of Mini Asymmetric Radial Keratotomy and Corneal Cross-linking for the Treatment of Keratoconus.
Korean J Ophthalmol
April 2019
Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.
Purpose: To investigate the long-term results (at least 5 years of follow-up) of the mini asymmetric radial keratotomy (MARK) and corneal cross-linking (CXL) combined intervention, also known as the 'Rome protocol,' for patients with progressive stage I and II keratoconus and contact lens intolerance.
Methods: This was a retrospective observational case series. Fifteen eyes of 12 patients were evaluated, with a mean follow-up of 6.
[Peripheral corneal cross-linking (P-CXL) for ultrathin corneas with severe keratoconus: a new technique].
Vestn Oftalmol
April 2018
Abbondanza Eye Centers, 58 Via Luigi Bodio, Rome, Italy, 00191.
Corneal cross-linking (CXL) is aimed at halting the progression of keratoconus and is widely considered to be the golden standard in its treatment. It is usually contraindicated, however, in patients with corneal thickness of less than 400 µm, leaving the ophthalmic surgeon no option, but to perform transepithelial CXL (epi-on), usually regarded as less effective. We report a novel approach for ultrathin corneas with severe keratoconus - peripheral corneal cross-linking (P-CXL), in which corneal epithelium is still removed but the apex of the cornea is left untouched.
View Article and Find Full Text PDFAim: To present the case of a 14-year-old boy with bilateral stage IV keratoconus, treated with a combined MARK + CXL intervention, without the need for a corneal transplantation.
Results: The left eye displays considerable improvements, with a follow-up of 13.5 years: Kmax is decreased by 5.